Mainly engaged in the basic research of viral hemorrhagic fever vaccine, diagnostic reagents and related viruses, as well as the prevention and control of viral hemorrhagic fever diseases at the national level. He has achieved fruitful results in the basic and applied research of molecular biology and molecular epidemiology of Hantavirus, won the third prize of national scientific and technological progress award and the second prize of the Ministry of Health, established a national monitoring network for epidemic hemorrhagic fever and dengue fever, and completed the monitoring scheme for hemorrhagic fever with renal syndrome and dengue fever and the national diagnostic standard for hemorrhagic fever. Monovalent and bivalent inactivated epidemic hemorrhagic fever vaccines have been successfully developed, obtained new drug certificates, and have been commercialized and marketed. The diagnostic kits of IgG, IgM and PCR for epidemic hemorrhagic fever, IgM and PCR for SARS virus were successfully developed. To establish the detection and diagnosis methods of viral hemorrhagic fever; Establish important diagnostic techniques for viral hemorrhagic fever including epidemic hemorrhagic fever, dengue fever, Ebola hemorrhagic fever, Marburg hemorrhagic fever and Lassa fever.

The pathogen of Hantavirus lung syndrome (a new infectious disease) was isolated for the first time and its gene rearrangement was confirmed. It was proved for the first time that Puumala Hantavirus was prevalent in China, and it was found that the non-coding region of Hantavirus gene was related to virus virulence, which played a theoretical guiding role in the development of new vaccines in China. Great achievements have also been made in the research of genetic engineering vaccine of Hantavirus, including the research of genetic engineering vaccine expressing virus-like particles (VLP) of Hantavirus in mammalian cells and the research of live vaccine based on measles virus.

He has successively presided over more than 973, 863, National Natural Science Foundation, emerging infectious diseases and other projects 10, and won the third prize of national scientific and technological progress: the second prize of scientific and technological progress of the Ministry of Health, the scientific and technological contribution award of the Army Institute of Infectious Diseases of the US Department of Defense, obtained 2 new drug certificates and applied for 5 patents. Four results were transmitted. Nearly 40 related research papers and works have been published at home and abroad. Train about 20 graduate students.